<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02090127</url>
  </required_header>
  <id_info>
    <org_study_id>AV-299-13-103S</org_study_id>
    <nct_id>NCT02090127</nct_id>
  </id_info>
  <brief_title>Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient</brief_title>
  <official_title>Expanded Access Protocol to Provide Ficlatuzumab to P05538 Patient 0001-000412</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AVEO Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AVEO Pharmaceuticals, Inc.</source>
  <brief_summary>
    <textblock>
      Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This treatment protocol will serve as a mechanism to continue to provide ficlatuzumab to
      patient 0001-000412, who was previously enrolled under protocol P05538 and whom the
      investigator believes is deriving clinical benefit from ficlatuzumab treatment.
    </textblock>
  </detailed_description>
  <overall_status>No longer available</overall_status>
  <study_type>Expanded Access</study_type>
  <condition>Mullerian Mixed Tumor of Ovary</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ficlatuzumab</intervention_name>
    <description>humanized anti-hepatocyte growth factor (HGF) monoclonal antibody IV administration at 16.5mg/kg every 2 weeks with a Â±2 day window around dosing dates, as long as subject is deriving clinical benefit as determined by the Investigator</description>
    <other_name>AV-299</other_name>
    <other_name>SCH 900105</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Per original P05538 protocol

        Exclusion Criteria:

          -  Per original P05538 protocol
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>START</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicaltrials.gov/show/NCT00725634</url>
    <description>Continued Access of Ficlatuzumab to P05538 Patient</description>
  </link>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2014</study_first_submitted>
  <study_first_submitted_qc>March 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2014</study_first_posted>
  <last_update_submitted>July 27, 2015</last_update_submitted>
  <last_update_submitted_qc>July 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Mixed Tumor, Mullerian</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

